{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:58:23Z","timestamp":1775152703442,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Etravirine (ETV) is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with reduced cross\u2010resistance to first\u2010generation NNRTIs, which has been primarily studied in randomized clinical trials and not in routine clinical settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ETV resistance\u2010associated mutations (RAMs) were investigated by analysing 6072 genotypic tests. The antiviral activity of ETV was predicted using different interpretation systems: International AIDS Society\u2010USA (IAS\u2010USA), Stanford, Rega and Agence Nationale de Recherches sur le Sida et les h\u00e9patites virales (ANRS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of ETV RAMs was higher in NNRTI\u2010exposed patients [44.9%, 95% confidence interval (CI) 41.0\u201348.9%] than in treatment\u2010na\u00efve patients (9.6%, 95% CI 8.5\u201310.7%). ETV RAMs in treatment\u2010na\u00efve patients mainly represent polymorphism, as prevalence estimates in genotypic tests for treatment\u2010na\u00efve patients with documented recent (&lt;1 year) infection, who had acquired HIV before the introduction of NNRTIs, were almost identical (9.8%, 95% CI 3.3\u201321.4). Discontinuation of NNRTI treatment led to a marked drop in the detection of ETV RAMs, from 51.7% (95% CI 40.8\u201362.6%) to 34.5% (95% CI 24.6\u201345.4%, <jats:italic>P<\/jats:italic>=0.032). Differences in prevalence among subtypes were found for V90I and V179T (<jats:italic>P<\/jats:italic>&lt;0.001). Estimates of restricted virological response to ETV varied among algorithms in patients with exposure to efavirenz (EFV)\/nevirapine (NVP), ranging from 3.8% (95% CI 2.5\u20135.6%) for ANRS to 56.2% (95% CI 52.2\u201360.1%) for Stanford. The predicted activity of ETV decreased as the sensitivity of potential optimized background regimens decreased. The presence of major IAS\u2010USA mutations (L100I, K101E\/H\/P and Y181C\/I\/V) reduced the treatment response at week 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Most ETV RAMs in drug\u2010na\u00efve patients are polymorphisms rather than transmitted RAMs. Uncertainty regarding predictions of antiviral activity for ETV in NNRTI\u2010treated patients remains high. The lowest activity was predicted for patients harbouring extensive multidrug\u2010resistant viruses, thus limiting ETV use in those who are most in need.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00756.x","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T02:05:03Z","timestamp":1251857103000},"page":"647-656","source":"Crossref","is-referenced-by-count":15,"title":["Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS)"],"prefix":"10.1111","volume":"10","author":[{"given":"AU","family":"Scherrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Von Wyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Yerly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"B\u00f6ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"B\u00fcrgisser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Klimkait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HC","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Ledergerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HF","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,27]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"266","article-title":"Antiretroviral drug resistance testing in adult HIV\u20101 infection","volume":"47","author":"Hirsch MS","year":"2008","journal-title":"2008 recommendations of an International AIDS Society-USA Panel"},{"key":"e_1_2_6_3_2","first-page":"555","article-title":"Antiretroviral treatment of adult HIV infection","volume":"300","author":"Hammer SM","year":"2008","journal-title":"2008 recommendations of the International AIDS Society-USA Panel"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.11.4999-5008.2001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2055"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/08892220260190308"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200312050-00009"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200311210-00011"},{"key":"e_1_2_6_9_2","first-page":"F1","article-title":"Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV\u20101","volume":"21","author":"Nadler JP","year":"2007","journal-title":"primary 24-week analysis"},{"key":"e_1_2_6_10_2","first-page":"29","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment\u2010experienced HIV\u20101\u2010infected patients in DUET\u20101","volume":"370","author":"Madruga JV","year":"2007","journal-title":"24-week results from a randomised, double-blind, placebo-controlled trial"},{"key":"e_1_2_6_11_2","first-page":"39","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment\u2010experienced HIV\u20101\u2010infected patients in DUET\u20102","volume":"370","author":"Lazzarin A","year":"2007","journal-title":"24-week results from a randomised, double-blind, placebo-controlled trial"},{"key":"e_1_2_6_12_2","unstructured":"VingerhoetsJ PeetersM AzijnHet al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET\u20101 and DUET\u20102 clinical trial data.17th International HIV Drug Resistance Workshop: Basic Principles & Clinical ImplicationsSitges Spain Antivir Ther2008;13(Suppl 3): P1\u2013P4 A1\u2010A178."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn297"},{"key":"e_1_2_6_14_2","first-page":"62","article-title":"Update of the drug resistance mutations in HIV\u20101","volume":"16","author":"Johnson VA","year":"2008","journal-title":"spring 2008"},{"key":"e_1_2_6_15_2","first-page":"138","article-title":"Update of the drug resistance mutations in HIV\u20101","volume":"16","author":"Johnson VA","year":"2008","journal-title":"Top HIV Med"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/135965350300800512","article-title":"Impact of genotypic resistance testing on selection of salvage regimen in clinical practice","volume":"8","author":"Haupts S","year":"2003","journal-title":"Antivir Ther"},{"key":"e_1_2_6_17_2","first-page":"533","article-title":"TORO","volume":"21","author":"Reynes J","year":"2007","journal-title":"ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals"},{"key":"e_1_2_6_18_2","first-page":"1169","article-title":"Efficacy and safety of darunavir\u2010ritonavir at week 48 in treatment\u2010experienced patients with HIV\u20101 infection in POWER 1 and 2","volume":"369","author":"Clotet B","year":"2007","journal-title":"a pooled subgroup analysis of data from two randomised trials"},{"key":"e_1_2_6_19_2","first-page":"466","article-title":"Durable efficacy of tipranavir\u2010ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment\u2010experienced HIV\u20101\u2010infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi\u2010drug reSistant patients with Tipranavir (RESIST) Studies","volume":"368","author":"Hicks CB","year":"2006","journal-title":"an analysis of combined data from two randomised open-label trials"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975"},{"key":"e_1_2_6_21_2","first-page":"863","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV\u20101 patients","volume":"353","author":"Ledergerber B","year":"1999","journal-title":"a prospective cohort study. Swiss HIV Cohort Study"},{"key":"e_1_2_6_22_2","first-page":"1782","article-title":"Emergence of HIV\u20101 drug resistance in previously untreated patients initiating combination antiretroviral treatment","volume":"167","author":"Von Wyl V","year":"2007","journal-title":"a comparison of different regimen types"},{"key":"e_1_2_6_23_2","first-page":"2223","article-title":"Transmission of HIV\u20101 drug resistance in Switzerland","volume":"21","author":"Yerly S","year":"2007","journal-title":"a 10-year molecular epidemiology survey"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350200700206","article-title":"A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV\u20101\u2010infected patients","volume":"7","author":"Van Laethem K","year":"2002","journal-title":"Antivir Ther"},{"issue":"3","key":"e_1_2_6_26_2","first-page":"A133","article-title":"HIV\u20101 genotype algorithms for prediction of etravirine susceptibility","volume":"13","author":"Benhamida J","year":"2008","journal-title":"novel mutations and weighting factors identified through correlations to phenotype"},{"issue":"3","key":"e_1_2_6_27_2","first-page":"A133","article-title":"Biological and clinical cut\u2010off analysis for etravirine in the PhenoSense HIV assay","volume":"13","author":"Coakley E","year":"2008","journal-title":"Antivir Ther"},{"issue":"3","key":"e_1_2_6_28_2","first-page":"A133","article-title":"Determination of phenotypic clinical cut\u2010offs analyses for etravirine","volume":"13","author":"Peeters M","year":"2008","journal-title":"pooled week 24 results of the DUET-1 and DUET-2 trials"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fa75df"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/135965350801300412","article-title":"Prevalence and risk factors for etravirine resistance among patients failing on non\u2010nucleoside reverse transcriptase inhibitors","volume":"13","author":"Lapadula G","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_6_31_2","unstructured":"PicchioG VingerhoetsJ StaesMet al. Prevalence of TMC125 resistance\u2010associated mutations in a large panel of clinical isolates.15th Conference on Retroviruses and Opportunistic Infections. Boston MA 2008 February [Abstract 866]."},{"key":"e_1_2_6_32_2","unstructured":"VingerhoetsJ ClotetB PeetersMet al. Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET\u20101 and DUET\u20102 Phase III clinical trials.11th European AIDS Conference. Madrid Spain October 2007 [Abstract P7.3\/05]."},{"key":"e_1_2_6_33_2","unstructured":"MarcelinA\u2010G FlandreP DescampsDet al. Factors associated with early virological response to etravirine in NNRTI\u2010experienced HIV\u2010infected patients.16th Conference on Retroviruses and Opportunistic Infections (CROI)Montreal Canada February 2009 [Abstract 645]."},{"key":"e_1_2_6_34_2","first-page":"1325","article-title":"HIV\u20101 drug resistance","volume":"191","author":"Harrigan PR","year":"2005","journal-title":"degree of underestimation by a cross-sectional versus a longitudinal testing approach"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00756.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00756.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:36:58Z","timestamp":1696876618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00756.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,27]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00756.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00756.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,27]]}}}